But deal with Samsung prevents US launch until mid-2023
Mylan and Biocon resolve biosimilar manufacturing issues
No-one can launch biosimilars until patent expires next year
South Korean firm looking to develop novel drugs
FDA approves Samsung Bioepis biosimilar.
Decision paves way for cheaper competitor in autumn 2018.
Samsung to take on patent thicket surrounding Humira.
South Korean firm trying to copy breast cancer blockbuster.